trial

Efficiency of Art-therapy in Psychotic Disorders

NCTId NCT02383095
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 9 (actual)
Sponsored by University Hospital, Strasbourg, France
Primary completion 2019-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
9 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2015-05-27
Primary completion
2019-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ART THERAPYmetacognitive therapy

Sponsors

University Hospital, Strasbourg, FranceLead Sponsor

Investigators

1
Anne GIERSCH, MD, PhDPrincipal Investigator

Sites

1 total
Strasbourg, France

Facts & assertions

4 sourced
Enrollment
9
Phase
NA
Primary Completion Date
2019-10
Status
TERMINATED
relationships
The graph out of here
drug
ART THERAPY
drug
metacognitive therapy
drug
lead_sponsor
University Hospital, Strasbourg, France
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Anne GIERSCH, MD, PhD
person